3D Printed Drugs Market

Table of Content

SECTION I: REPORT OVERVIEW

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Introduction

2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative

2.4.2.3. Advantages

2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions

2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Healthcare Providers

2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity

2.4.3. Analytical Tools and Databases

3. MARKET DYNAMICS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach

3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)

3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis

3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation

3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of 3D Printed Drugs
6.2.1. Advantages and Limitation of 3D Printed Drugs
6.2.2. Current Status of 3D Printed Drugs
6.2.3. Current Limitations and Challenges of 3D Printed Drugs
6.2.4. Regulatory Landscape of 3D Printed Drugs

6.3. Future Perspective

7. REGULATORY SCENARIO

SECTION III: MARKET OVERVIEW

8. COMPREHENSIVE DATABASE OF LEADING PLAYERS

9. COMPETITIVE LANDSCAPE
9.1. Chapter Overview
9.2. 3D Printed Drugs: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters

9.2.4. 3D Printed Drugs Market: Overall Market Landscape
9.2.4.1. Analysis by Dosage Form Type
9.2.4.2. Analysis by Technology Type
9.2.4.3. Analysis by Application Type
9.2.4.4. Analysis by End User

10. PORTER'S FIVE FORECES ANALYSIS

11. COMPETITIVE COMPETITIVENESS ANALYSIS

12. STARTUP ECOSYSTEM IN THE 3D PRINTED DRUGS MARKET
12.1. 3D Printed Drugs: Market Landscape of Startups
12.1.1. Analysis by Year of Establishment
12.1.2. Analysis by Company Size
12.1.3. Analysis by Company Size and Year of Establishment
12.1.4. Analysis by Location of Headquarters
12.1.5. Analysis by Company Size and Location of Headquarters
12.1.6. Analysis by Ownership Structure

12.2. Key Findings

SECTION IV: COMPANY PROFILES

13. COMPANY PROFILES
13.1. Chapter Overview
13.2. 3DR Holdings
13.2.1. Company Overview
13.2.2. Company Mission
13.2.3. Company Footprint
13.2.4. Management Team
13.2.5. Contact Details
13.2.6. Financial Performance
13.2.7. Operating Business Segments
13.2.8. Service / Product Portfolio (project specific)
13.2.9. MOAT Analysis
13.2.10. Recent Developments and Future Outlook

* similar detail is presented for other below mentioned companies based on information in the public domain

13.3. 3D Systems
13.4. Anatomics
13.5. AstraZeneca
13.6. Aprecia Pharmaceuticals
13.7. Affinity Therapeutics
13.8. Biomedical Modeling
13.9. BioDuro
13.10. Cyfuse Biomedical
13.11. Cycle Pharmaceuticals
13.12. Envision TEC
13.13. Extend Biosciences
13.14. FabRx
13.15. GlaxoSmithKline
13.16. Hewlett Packard Caribe
13.17. Materialize
13.18. Merck
13.19. Organovo Holdings
13.20. Osmotica Pharmaceuticals
13.21. Proto Labs
13.22. Rokit Healthcare
13.23. Renishaw
13.24. Stratasys
13.25. Siemens
13.26. TVASTA
13.27. Triastek
13.28. Yissum
13.29. Zortrax

SECTION V: MARKET TRENDS

14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology

14.3. 3D Printed Drugs: Patent Analysis
14.3.1. Analysis by Patent Publication Year
14.3.2. Analysis by Type of Patent and Patent Publication Year
14.3.3. Analysis by Patent Application Year
14.3.4. Analysis by Patent Jurisdiction
14.3.5. Analysis by CPC Symbols
14.3.6. Analysis by Type of Applicant
14.3.7. Leading Industry Players: Analysis by Number of Patents
14.3.8. Leading Individual Assignees: Analysis by Number of Patents

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models

15.3. 3D Printed Drugs: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Type of Partner
15.3.5. Analysis by Location of Headquarters of Partner
15.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
15.3.7. Most Active Players: Analysis by Number of Partnerships

15.3.8. Regional Analysis
15.3.8.1. Intercontinental and Intracontinental Deals
15.3.8.2. Local and International Deals

16. GRANT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology

16.3. 3D Printed Drugs: Grant Analysis
16.3.1. Analysis by Year of Grant Award
16.3.2. Analysis by Amount Awarded
16.3.3. Analysis by Support Period
16.3.4. Analysis by Support Period and Funding Institute Center
16.3.5. Analysis by Type of Grant Application
16.3.6. Analysis by Purpose of Grant Award
16.3.7. Analysis By Activity Code
16.3.8. Analysis by NIH Spending Category
16.3.9. Analysis by Study Section Involved
16.3.10. Popular NIH Departments: Analysis by Number of Grants
16.3.11. Analysis by Type of Recipient Organization
16.3.12. Prominent Program Officers: Analysis by Number of Grants
16.3.13. Popular Recipient Organizations: Analysis by Number of Grants
16.3.14. Popular Recipient Organizations: Analysis by Grant Amount
16.3.15. Analysis by Region of Recipient Organizations

SECTION VI: MARKET OPPORTUNITY ANALYSIS

17. GLOBAL 3D PRINTED DRUGS MARKET
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Trends Disruption Impacting Market
17.4. Demand Side Trends
17.5. Supply Side Trends
17.6. Global 3D Printed Drugs Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

17.7. Multivariate Scenario Analysis
17.7.1. Conservative Scenario
17.7.2. Optimistic Scenario

17.8. Investment Feasibility Index
17.9. Key Market Segmentations

18. MARKET OPPORTUNITIES BASED ON TYPE OF PRODUCT
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Revenue Shift Analysis
18.4. Market Movement Analysis
18.5. Penetration-Growth (P-G) Matrix
18.6. 3D Printed Drugs Market for 3D Printed Tablets: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.7. 3D Printed Drugs Market for 3D Printed Capsules: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.8. 3D Printed Drugs Market for 3D Printed Multi Drug Implants: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.9. 3D Printed Drugs Market for 3D Printed Nanoparticles: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.10. 3D Printed Drugs Market for 3D Printed Solutions: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.11. 3D Printed Drugs Market for Other 3D Printed Drug Dosage Forms: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

18.12. Data Triangulation and Validation
18.12.1. Secondary Sources
18.12.2. Primary Sources
18.12.3. Statistical Modeling

19. MARKET OPPORTUNITIES BASED ON TYPE OF TECHNOLOGY
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Revenue Shift Analysis
19.4. Market Movement Analysis
19.5. Penetration-Growth (P-G) Matrix
19.6. 3D Printed Drugs Market for Inkjet 3D Printed Technologies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.7. 3D Printed Drugs Market for Direct Write 3D Printed Technologies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.8. 3D Printed Drugs Market for Zipdose 3D printed Technologies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.9. 3D Printed Drugs Market for Thermal Inkjet 3D Printed Technologies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.10. 3D Printed Drugs Market for 3D Printed Technologies Based on Fused Deposition Modeling: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.11. 3D Printed Drugs Market for Powder Bed 3D Printed Technologies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.12. 3D Printed Drugs Market for Stereo Lithography 3D Printed Technologies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19.13. 3D Printed Drugs Market for Semi Solid Extrusion 3D Printed Technologies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.14. Data Triangulation and Validation
19.14.1. Secondary Sources
19.14.2. Primary Sources
19.14.3. Statistical Modeling

20. MARKET OPPORTUNITIES BASED ON TYPE OF APPLICATION
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix
20.6. 3D Printed Drugs Market for Neurology: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.7. 3D Printed Drugs Market for Orthopedic: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.8. 3D Printed Drugs Market for Dental: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.9. 3D Printed Drugs Market for Other Applications: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.10. Data Triangulation and Validation
20.10.1. Secondary Sources
20.10.2. Primary Sources
20.10.3. Statistical Modeling

21. MARKET OPPORTUNITIES BASED ON END USER
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. 3D Printed Drugs Market for Hospitals & Clinics: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.7. 3D Printed Drugs Market for Research Laboratories: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.8. 3D Printed Drugs Market for Other End Users: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.9. Data Triangulation and Validation
21.9.1. Secondary Sources
21.9.2. Primary Sources
21.9.3. Statistical Modeling

22. MARKET OPPORTUNITIES FOR 3D PRINTED DRUGS IN NORTH AMERICA
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix

22.6. 3D Printed Drugs Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.1. 3D Printed Drugs Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.2. 3D Printed Drugs Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.6.3. 3D Printed Drugs Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.7. Data Triangulation and Validation

23. MARKET OPPORTUNITIES FOR 3D PRINTED DRUGS IN EUROPE
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix

23.6. 3D Printed Drugs Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.1. 3D Printed Drugs Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.2. 3D Printed Drugs Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.3. 3D Printed Drugs Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.4. 3D Printed Drugs Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.5. 3D Printed Drugs Market in The UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.6.6. 3D Printed Drugs Market in Rest of the Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.7. Data Triangulation and Validation

24. MARKET OPPORTUNITIES FOR 3D PRINTED DRUGS IN ASIA-PACIFIC
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Revenue Shift Analysis
24.4. Market Movement Analysis
24.5. Penetration-Growth (P-G) Matrix

24.6. 3D Printed Drugs Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.1. 3D Printed Drugs Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.2. 3D Printed Drugs Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.3. 3D Printed Drugs Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.4. 3D Printed Drugs Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.5. 3D Printed Drugs Market in Australia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.6. 3D Printed Drugs Market in Russia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.7. 3D Printed Drugs Market in Thailand: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.8. 3D Printed Drugs Market in Malaysia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.9. 3D Printed Drugs Market in Indonesia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.6.10. 3D Printed Drugs Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.7. Data Triangulation and Validation

25. MARKET OPPORTUNITIES FOR 3D PRINTED DRUGS IN MIDDLE EAST AND NORTH AFRICA (MENA)
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Revenue Shift Analysis
25.4. Market Movement Analysis
25.5. Penetration-Growth (P-G) Matrix

25.6. 3D Printed Drugs Market in Middle East and North Africa (MENA): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.1. 3D Printed Drugs Market in Iran: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.2. 3D Printed Drugs Market in Saudi Arabia: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.3. 3D Printed Drugs Market in Egypt: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.7. Data Triangulation and Validation

26. MARKET OPPORTUNITIES FOR 3D PRINTED DRUGS IN LATIN AMERICA
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Revenue Shift Analysis
26.4. Market Movement Analysis
26.5. Penetration-Growth (P-G) Matrix

26.6. 3D Printed Drugs Market in Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.1. 3D Printed Drugs Market in Brazil: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.2. 3D Printed Drugs Market in Argentina: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.3. 3D Printed Drugs Market in Rest of Latin America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.7. Data Triangulation and Validation

SECTION VII: STRATEGIC TOOLS

27. ROOTS STRATEGIC RECOMMENDATIONS

SECTION VIII: OTHER EXCLUSIVE INSIGHTS

28. INSIGHTS FROM PRIMARY RESEARCH

29. REPORT CONCLUSION

SECTION IX: APPENDIX

30. TABULATED DATA

31. LIST OF COMPANIES AND ORGANIZATIONS

32. CUSTOMIZATION OPPORTUNITIES

33. ROOTS SUBSCRIPTION SERVICES

34. AUTHOR DETAILS